To determine the induction of anti-tumor T-cell responses, we harvested the splenocytes 14 days after tumor challenge and re-stimulated purified CD4+ or CD8+ T cells with purified splenic CD11c+ cells pulsed with peptides mix (HIV gag, HER2, or neu) or NT2.5 tumor lysate. The gene discussed is ERBB2; the disease is neoplasm.